Abstract | OBJECTIVE: METHOD: RESULTS: Strong, mostly time-dependent negative correlations were found for the plasma levels of sertraline and N-desmethylsertraline with PF4 (week 6: r=-0.69 and -0.33, respectively; week 16: r=-0.63 for both), beta-TG (week 6: r=-0.43 and -0.29; week 16: r=-0.66 and -0.57), PECAM-1 (week 6: r=-0.82 and -0.49; week 16: r=-0.60 for both), P-selectin (week 6: r=-0.82 and -0.49; week 16: r=-0.73 and -0.43), and TxB(2) (week 6: r=-0.66 and -0.59; and week 16: r=-0.64 and -0.41). Regression analysis revealed some borderline correlations for endothelial markers such as 6-keto- PGF1alpha and E-selectin and a positive correlation for VCAM-1. CONCLUSIONS: This is the first documented evidence that plasma release of platelet/endothelial biomarkers is directly related to the levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. The clinical significance of these findings should be assessed in the setting of a randomized clinical trial.
|
Authors | Victor L Serebruany, Raymond F Suckow, Thomas B Cooper, Christopher M O'Connor, Alex I Malinin, K Ranga R Krishnan, Louis T van Zyl, Vladimir Lekht, Alexander H Glassman, Sertraline Antidepressant Heart Attack Randomized Trial |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 162
Issue 6
Pg. 1165-70
(Jun 2005)
ISSN: 0002-953X [Print] United States |
PMID | 15932816
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Serotonin Uptake Inhibitors
- desmethylsertraline
- Sertraline
|
Topics |
- Biomarkers
(blood, metabolism)
- Blood Platelets
(drug effects, metabolism)
- Coronary Disease
(blood, metabolism)
- Coronary Vessels
(drug effects, metabolism)
- Endothelium, Vascular
(drug effects, metabolism)
- Humans
- Selective Serotonin Reuptake Inhibitors
(blood, pharmacology, therapeutic use)
- Sertraline
(analogs & derivatives, blood, pharmacology, therapeutic use)
|